Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation ...

New treatments, such as obeticholic acid, are being studied and have demonstrated the ability to reduce liver fat and inflammation.” Omega-3s: Consuming fish or Cod Liver Oil capsules regularly ...

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation, though ...

Intercept Therapeutics’ efforts with FXR agonist Ocaliva (obeticholic acid) ended in disappointment when the US Food and Drug Administration (FDA) rejected the drug for MASH in 2023, forcing the ...

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation ...

Researchers for the ongoing 30-year Diabetes Prevention Program found out last week that the NIH canceled funding for the ...

The following is a summary of “Efficacy and Safety of Obeticholic Acid for Treating Hepatic Steatosis in Patients with Familial Partial Lipodystrophy,” published in the March 2025 issue of Journal of ...

The European Commission revoked the conditional marketing authorisation for Ocaliva (obeticholic acid) earlier this year on the grounds that its benefits no longer outweighed its risks as a ...

Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195] Technology appraisal guidance TBC NY-ESO-1 T-cells for treating synovial sarcoma ID1286 Technology ...